Share on StockTwits

ADMA Biologics (NASDAQ:ADMA) CEO Adam S. Grossman bought 1,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were purchased at an average price of $9.50 per share, for a total transaction of $9,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Maxim Group reiterated a “buy” rating on shares of ADMA Biologics in a research note on Friday, July 11th. They now have a $15.00 price target on the stock.

ADMA Biologics (NASDAQ:ADMA) traded up 1.08% on Tuesday, hitting $9.35. 5,800 shares of the company’s stock traded hands. ADMA Biologics has a 52 week low of $6.52 and a 52 week high of $10.75. The stock’s 50-day moving average is $9.93 and its 200-day moving average is $8.87. The company’s market cap is $86.9 million.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.